PhD Studentship: Protein Degraders: The University of Dundee is offering a fully funded PhD opportunity focused on investigating the efflux transporter liabilities of targeted protein degraders in the context of neurodegenerative diseases. This scholarship provides an excellent opportunity for students interested in molecular biology, drug design, and drug profiling assays, combining academic research with industrial collaboration.
PhD Studentship: Investigating Efflux Transporter Liabilities of Targeted Protein Degraders
Designation
PhD Studentship
| Details | Information |
|---|---|
| Funding Availability | Fully Funded |
| Duration | 4 years |
| Annual Stipend | £19,236 (tax-free) |
| Start Date | September 2025 |
| Application Deadline | 6 December 2024 |
Research Area
Neurodegenerative diseases, Targeted Protein Degradation, Drug Design
Location
University of Dundee, School of Life Sciences, Centre for Targeted Protein Degradation (CeTPD)
Eligibility/Qualification
- Applicants must have a degree equivalent to Honours or Masters in a relevant discipline.
Description
This PhD project aims to explore the potential of bifunctional degraders in treating neurodegenerative diseases like Alzheimer’s and Parkinson’s, focusing on overcoming challenges related to brain penetration posed by efflux transporter proteins in the blood-brain barrier. The research will include:
- Developing methods to identify bifunctional degraders likely to cross the blood-brain barrier.
- Creating design rules to enhance the brain access of these molecules to maximize their clinical impact.
The project will be conducted under the supervision of Dr. William Farnaby in collaboration with Promega Corporation and Professor Kevin Read.
How to Apply
Interested candidates can apply through the University of Dundee’s application portal. Information about fee status assessments can be found on the university’s website.
Last Date to Apply
6 December 2024
For informal enquiries, please contact Dr. William Farnaby at w.farnaby@dundee.ac.uk. More information on Dr. Farnaby’s group and the research can be found at:
